Gland Pharma · NSE: GLAND · BSE: 543245
Q4 FY25 results · Jan–Mar 2025
Gland Pharma reported revenue from operations of ₹1,424.91 crore (down 7.3% from Q4 FY24) and net profit of ₹186.54 crore (down 3.1% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,424.91 | 1,537.45 | −7.3% | 1,384.05 | +3.0% |
| Other income | 44.03 | 42.15 | +4.5% | 58.49 | −24.7% |
| Total income | 1,468.94 | 1,579.60 | −7.0% | 1,442.55 | +1.8% |
| Profit before tax | 288.33 | 298.23 | −3.3% | 299.30 | −3.7% |
| Net profit for the period | 186.54 | 192.42 | −3.1% | 204.69 | −8.9% |
| EPS, basic (₹) | 11.32 | 11.68 | −3.1% | 12.42 | −8.9% |
| Net margin (%) | 13.1 | 12.5 | 14.8 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,030.35 | 1,174.83 | −12.3% | 1,010.78 | +1.9% |
| Other income | 43.72 | 46.95 | −6.9% | 65.06 | −32.8% |
| Total income | 1,074.07 | 1,221.79 | −12.1% | 1,075.85 | −0.2% |
| Profit before tax | 391.32 | 432.69 | −9.6% | 394.13 | −0.7% |
| Net profit for the period | 290.00 | 321.41 | −9.8% | 295.12 | −1.7% |
| EPS, basic (₹) | 17.60 | 19.51 | −9.8% | 17.91 | −1.7% |
| Net margin (%) | 28.1 | 27.4 | 29.2 |
Consolidated
- Filed with BSE
- 20 May 2025, 21:34 IST
- Board meeting
- 20 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 May 2025, 21:34 IST
- Board meeting
- 20 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE